SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020

SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023

Published:2024-07-11 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Carreño Juan Manuel,Wagner Abram L.^ORCID,Monahan Brian^ORCID,Singh Gagandeep^ORCID,Floda Daniel,Gonzalez-Reiche Ana S.^ORCID,Tcheou Johnstone,Raskin Ariel^ORCID,Bielak Dominika,Morris Sara,Fried Miriam,Yellin Temima^ORCID,Sullivan Leeba, ,Amanat Fatima,Arunkumar Guha Asthagiri,Capuano Christina,Ehrenhaus Jordan,Fabre Shelcie,Hernandez Matthew M.,Jiang Kaijun,Lerman Brian,McMahon Meagan,Stadlbauer Daniel,Tan Jessica,Teo Catherine,Twyman Kathryn,Sordillo Emilia Mia^ORCID,Gordon Aubree^ORCID,van Bakel Harm^ORCID,Simon Viviana^ORCID,Krammer Florian^ORCID

Abstract

AbstractSero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.

Funder

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-50052-2.pdf

Reference37 articles.

1. Thompson, C. N. et al. COVID-19 outbreak - New York City, February 29-June 1, 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1725–1729 (2020).

2. Dalva-Baird, N. P., Alobuia, W. M., Bendavid, E. & Bhattacharya, J. Racial and ethnic inequities in the early distribution of U.S. COVID-19 testing sites and mortality. Eur. J. Clin. Invest. 51, e13669 (2021).

3. Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162–177 (2023).

4. Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020).

5. Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827.e819 (2020).